articleThe LancetNov 1, 2008Closed access

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

ESEdward S. KimVHVera HirshTMTony MokMAMark A. SocinskiRGRadj Gervais

The University of Texas MD Anderson Cancer Center · McGill University Health Centre · +15 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,243
total citations
FWCI
112.40
Percentile
100%
References
31
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Gefitinib
  • Docetaxel
  • Medicine
  • Lung cancer
  • Internal medicine
  • Regimen
  • Hazard ratio
  • Population
No related works found for this paper.

Funding